|
|
 Previous Article | Table of Contents | Next Article 
Ki-B5: a monoclonal antibody unrelated to CD45 recognizes normal and
neoplastic human B cells in routine paraffin sections
ML Hansmann, HH Wacker, J Gralla, H Lumbeck, M Kossmahl, HJ Heidebrecht, HJ Radzun and MR Parwaresch
Department of Pathology, Christian Albrechts University, Kiel, Germany.
In the search for immunoreagents appropriate for the histopathologic
diagnosis of malignant B-cell lymphomas in routinely processed paraffin
sections, a new monoclonal antibody, Ki-B5, was generated using a high-
grade B-cell lymphoma as the immunogene. Ki-B5 is a mouse IgG1/kappa that
recognizes five protein fractions of about 84, 82, 55, 48, and 27 Kd after
biosynthetic radiolabeling and immunoprecipitation. Protein fractions with
the molecular weights of approximately 84 and 82 Kd were expressed on the
cell surface and show that Ki-B5 is probably unrelated to CD45. It was
possible through electron microscopy to visualize the membrane-bound
portion of Ki-B5. Extensive immunohistologic studies on normal human tissue
and various neoplasias demonstrated the high specificity of Ki-B5 to normal
human B cells and a minor subgroup of plasma cells. Except for ML-2, which
is a myelomonocytic human cell line, Ki-B5 exclusively recognized the
B-cell lineage, including EB-3, BALL-1, and NALM-1. All carcinomas,
sarcomas, and malignant melanomas tested with Ki-B5 were negative. Although
normal granulocytes and monocytes were constantly negative, three of eight
myelomonocytic leukemias coreacted with this antibody. Eight of the 57
T-cell lymphomas studied were positive to Ki-B5. Five were classified as
lymphoblastic, two represented T8-CLL, and one was classified as
immunoblastic T-cell lymphoma. Only 3 of 126 cases of B-cell lymphoma,
including rare types not considered in the current classifications, were
negative to Ki-B5. Plasmacytomas were also negative, except for one case.
Irrespective of the cases of lymphoblastic lymphoma and plasmacytoma, Ki-B5
represents a new monoclonal antibody appropriate for the diagnosis and
immunophenotyping of malignant lymphomas in routinely processed paraffin
sections.
Volume 77,
Issue 4,
pp. 809-817,
02/15/1991
Copyright © 1991 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
K. Seidemann, M. Tiemann, I. Lauterbach, G. Mann, I. Simonitsch, K. Stankewitz, M. Schrappe, M. Zimmermann, C. Niemeyer, R. Parwaresch, et al.
Primary Mediastinal Large B-Cell Lymphoma With Sclerosis in Pediatric and Adolescent Patients: Treatment and Results From Three Therapeutic Studies of the Berlin-Frankfurt-Munster Group
J. Clin. Oncol.,
May 1, 2003;
21(9):
1782 - 1789.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Seidemann, M. Tiemann, M. Schrappe, E. Yakisan, I. Simonitsch, G. Janka-Schaub, W. Dorffel, M. Zimmermann, G. Mann, H. Gadner, et al.
Short-pulse B-non-Hodgkin lymphoma-type chemotherapy is efficacious treatment for pediatric anaplastic large cell lymphoma: a report of the Berlin-Frankfurt-Munster Group Trial NHL-BFM 90
Blood,
June 15, 2001;
97(12):
3699 - 3706.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
